Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Contemporary Transcatheter Interventions
share announcement

Contemporary Transcatheter Interventions

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 5756

Special Issue Editors

Dr. Alexandru Achim

E-Mail Website
Guest Editor
Cardiology Department, University of Basel, Kantonsspital Baselland, 4410 Liestal, Switzerland
Interests: coronary interventions; vascular access; interventional cardiology; atherosclerosis
Dr. Zoltan Ruzsa

E-Mail Website
Guest Editor
Department of Internal Medicine, Invasive Cardiology Division, University of Szeged, 6720 Szeged, Hungary
Interests: vascular medicine; cardiovascular system; stents; angiography; carotid arteries; coronary angioplasty; vascular diseases
Dr. Jef Van den Eynde

E-Mail Website
Guest Editor
Department of Cardiovascular Sciences, KU Leuven, 3000 Leuven, Belgium
Interests: vascular medicine; small animal surgery; heart failure; cardiovascular disease; congenital cardiac surgery

Special Issue Information

Dear Colleagues,

The term “transcatheter interventions” covers all the progress made in the last two decades in interventional cardiology, radiology, neuroradiology, and angiology. Practically, in recent times, any area of the body can be reached with a catheter, and more and more vascular operations are being replaced by minimally invasive interventions of the latest generation. The field has exploded; more and more instruments and techniques are being utilized, and this dynamic must be matched with robust studies. We target this need with this Special Issue where we practically meet at the confluence of all "interventional" specialties to offer the academic community and our patients studies, commentaries, reviews, and case reports that strengthen the evidence and the level of recommendation of these interventions which we perform on an everyday basis.

We thus invite all operators and physicians with percutaneous expertise to collate some high-quality studies. We accept and encourage all topics that converge all medical specialties with emphasis on contemporary concepts appearing in each sub-field (complex coronary interventions, valves, structural cardiac interventions, tumors, peripheral ischemia, aorta, neuroradiology, etc.). We promise in return a professional submission experience, an already established standard of MDPI.

Dr. Alexandru Achim
Dr. Zoltan Ruzsa
Dr. Jef Van den Eynde
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • coronary angioplasty
  • vascular diseases
  • coronary heart disease
  • atherosclerosis
  • interventional cardiology
  • vascular access
  • percutaneous coronary intervention
  • stents
  • transcatheter aortic valve implantation
  • carotid angioplasty
  • angiology
  • interventional radiology

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1057 KiB  
Article
The Impact of Monocyte to High-Density Lipoprotein Cholesterol Ratio on All-Cause and Cardiovascular Mortality in Patients with Transcatheter Aortic Valve Replacement
by Denisa Bianca Mercean, Raluca Tomoaia, Adela Mihaela Şerban, Ştefan Dan Cezar Moţ, Radu Hagiu and Carmen Mihaela Mihu
J. Pers. Med. 2023, 13(6), 989; https://doi.org/10.3390/jpm13060989 - 13 Jun 2023
Cited by 1 | Viewed by 917
Abstract
Background: Inflammation plays a significant role in the pathogenesis of aortic stenosis. This study aimed to investigate the prognostic value of the monocyte-HDL cholesterol ratio (MHR), a new inflammatory marker, in severe aortic stenosis (AS) patients who underwent transcatheter aortic valve replacement (TAVR). [...] Read more.
Background: Inflammation plays a significant role in the pathogenesis of aortic stenosis. This study aimed to investigate the prognostic value of the monocyte-HDL cholesterol ratio (MHR), a new inflammatory marker, in severe aortic stenosis (AS) patients who underwent transcatheter aortic valve replacement (TAVR). Methods: A total of 125 patients with severe AS who underwent TAVR were assessed. Clinical, echocardiographic and laboratory data relevant to the research were retrospectively obtained from the patients’ records. The MHR was determined by dividing the absolute monocyte count by the HDL-C value. The primary endpoints were overall and cardiovascular mortality. Results: During a median follow-up time of 39 months, primary endpoints were developed in 51 (40.8%) patients (overall mortality) and 21 (16.8%) patients (cardiovascular mortality). A receiver operating characteristic (ROC) analysis showed that by using a cut-off level of 16.16, the MHR predicted the all-cause mortality with a sensitivity of 50.9% and specificity of 89.1%. In predicting cardiovascular mortality, the MHR exhibited a sensitivity of 80.9% and specificity of 70.1% when a cut-off level of 13.56 was used. In the multivariate analysis, the MHR (p < 0.0001; 95% CI: 1.06–1.15) and atrial fibrillation (p = 0.018; 95% CI: 1.11–3.38) were found to be significant predictors of overall mortality. Conclusions: This study showed a significant elevation in the MHR among patients who experienced all-cause and cardiovascular mortality and this ratio emerged as an independent predictor of all-cause death in patients with severe AS undergoing TAVR. Full article
(This article belongs to the Special Issue Contemporary Transcatheter Interventions)
►▼ Show Figures

Figure 1

12 pages, 2118 KiB  
Article
The Degree of Stent Apposition Measured by Stent Enhancement at the Level of the Side Branch as a Novel Predictor of Procedural Success in Left Main PCI
by Ștefan Dan Cezar Moț, Adela Mihaela Șerban, Alexandra Dădârlat-Pop, Raluca Tomoaia and Dana Pop
J. Pers. Med. 2023, 13(5), 791; https://doi.org/10.3390/jpm13050791 - 03 May 2023
Cited by 1 | Viewed by 1481
Abstract
Background: Stent enhancement techniques allow adequate visualization of stent deformation or incomplete stent expansion at the ostium of the side branch. Measuring the stent enhancement side branch length (SESBL) could reflect procedural success in terms of optimal stent expansion and apposition with better [...] Read more.
Background: Stent enhancement techniques allow adequate visualization of stent deformation or incomplete stent expansion at the ostium of the side branch. Measuring the stent enhancement side branch length (SESBL) could reflect procedural success in terms of optimal stent expansion and apposition with better long-term outcomes. A longer SESBL may reflect a better stent apposition at the polygon of confluence and at the side branch (SB) ostium. Methods: We evaluated 162 patients receiving the left main (LM) provisional one-stent technique and measured the SESBL, dividing them into two groups: SESBL≤ 2.0 mm and SESBL > 2.0 mm. Results: The mean SESBL was 2.0 ± 1.2 mm. More than half of the bifurcations had both main and side branch lesions (Medina 1-1-1) (84 patients, 51.9%) and the length of the SB disease was 5.2 ±1.8 mm. Kissing balloon inflation (KBI) was performed in 49 patients (30.2%). During follow-up (12 months), there was a significantly higher rate of cardiac death in the SESBL ≤ 2.0 mm group (p = 0.02) but no significant difference in all major adverse cardiovascular events (MACEs) (p = 0.7). KBI did not influence the outcomes (p = 0.3). Conclusion: Suboptimal SESBL is positively correlated with worse outcomes and SB compromise. This novel sign could aid the LM operator to assess the level of stent expansion at the ostium of the SB in the absence of intracoronary imaging. Full article
(This article belongs to the Special Issue Contemporary Transcatheter Interventions)
►▼ Show Figures

Figure 1

10 pages, 582 KiB  
Article
Oral Health of Patients Undergoing Percutaneous Coronary Intervention—A Possible Link between Periodontal Disease and In-Stent Restenosis
by Ferenc Tamás Nagy, Dorottya Gheorghita, Lalli Dharmarajan, Gábor Braunitzer, Alexandru Achim, Zoltán Ruzsa and Márk Ádám Antal
J. Pers. Med. 2023, 13(5), 760; https://doi.org/10.3390/jpm13050760 - 28 Apr 2023
Cited by 2 | Viewed by 1004
Abstract
Introduction: There is a well-documented association between coronary artery disease (CHD) and periodontal disease (PD) mediated by common inflammatory pathways. This association, however, has not been investigated extensively in the special context of in-stent restenosis. This study aimed to investigate the periodontal status [...] Read more.
Introduction: There is a well-documented association between coronary artery disease (CHD) and periodontal disease (PD) mediated by common inflammatory pathways. This association, however, has not been investigated extensively in the special context of in-stent restenosis. This study aimed to investigate the periodontal status of patients undergoing percutaneous coronary intervention (PCI) for restenotic lesions. Methods and Results: We enrolled 90 patients undergoing percutaneous coronary intervention and 90 age- and gender-matched healthy controls in the present study. All subjects received a full-mouth examination by a periodontist. Plaque index, periodontal status, and tooth loss were determined. The periodontal state was significantly worse (p < 0.0001) in the PCI group, and each periodontal stage increased the odds of belonging to the PCI group. This effect of PD was independent of diabetes mellitus, another strong risk factor for CAD. The PCI group was further divided into two subgroups: PCI for restenotic lesions (n = 39) and PCI for de novo lesions (n = 51). Baseline clinical and procedural characteristics were comparable between the two PCI subgroups. A significant (p < 0.001) association was found between the PCI subgroup and the severity of periodontal disease, with the incidence of severe PD reaching 64.1%. Conclusions: Patients undergoing PCI for in-stent restenosis exhibit more severe forms of periodontal disease not only as compared to healthy controls but also as compared to patients stented for de novo lesions. The potential causality between PD and restenosis must be studied in larger prospective studies. Full article
(This article belongs to the Special Issue Contemporary Transcatheter Interventions)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 298 KiB  
Review
Is There an Advantage of Ultrathin-Strut Drug-Eluting Stents over Second- and Third-Generation Drug-Eluting Stents?
by Flavius-Alexandru Gherasie, Chioncel Valentin and Stefan-Sebastian Busnatu
J. Pers. Med. 2023, 13(5), 753; https://doi.org/10.3390/jpm13050753 - 28 Apr 2023
Cited by 4 | Viewed by 1785
Abstract
In patients undergoing percutaneous coronary intervention, the second-generation drug-eluting stents (DES) are considered the gold standard of care for revascularization. By reducing neointimal hyperplasia, drug-eluting coronary stents decrease the need for repeat revascularizations compared with conventional coronary stents without an antiproliferative drug coating. [...] Read more.
In patients undergoing percutaneous coronary intervention, the second-generation drug-eluting stents (DES) are considered the gold standard of care for revascularization. By reducing neointimal hyperplasia, drug-eluting coronary stents decrease the need for repeat revascularizations compared with conventional coronary stents without an antiproliferative drug coating. It is important to note that early-generation DESs were associated with an increased risk of very late stent thrombosis, most likely due to delayed endothelialization or a delayed hypersensitivity reaction to the polymer. Studies have shown a lower risk of very late stent thrombosis with developing second-generation DESs with biocompatible and biodegradable polymers or without polymers altogether. In addition, research has indicated that thinner struts are associated with a reduced risk of intrastent restenosis and angiographic and clinical results. A DES with ultrathin struts (strut thickness of 70 µm) is more flexible, facilitates better tracking, and is more crossable than a conventional second-generation DES. The question is whether ultrathin eluting drug stents suit all kinds of lesions. Several authors have reported that improved coverage with less thrombus protrusion reduced the risk of distal embolization in patients with ST-elevation myocardial infarction (STEMI). Others have described that an ultrathin stent might recoil due to low radial strength. This could lead to residual stenosis and repeated revascularization of the artery. In CTO patients, the ultrathin stent failed to prove non-inferiority regarding in-segment late lumen loss and showed statistically higher rates of restenosis. Ultrathin-strut DESs with biodegradable polymers have limitations when treating calcified (or ostial) lesions and CTOs. However, they also possess certain advantages regarding deliverability (tight stenosis, tortuous lesions, high angulation, etc.), ease of use in bifurcation lesions, better endothelialization and vascular healing, and reducing stent thrombosis risk. In light of this, ultrathin-strut stents present a promising alternative to existing DESs of the second and third generation. The aims of the study are to compare ultrathin eluting stents with second- and third-generation conventional stents regarding procedural performance and outcomes based on different lesion types and specific populations. Full article
(This article belongs to the Special Issue Contemporary Transcatheter Interventions)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop